Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

California biomedical industry report

This article was originally published in The Gray Sheet

Executive Summary

Survey of biomedical companies by the California Healthcare Institute and PricewaterhouseCoopers finds that 78% of respondents believe mergers and acquisitions will increase in the state over the next two years. Meanwhile, 40% of participants thought the number of initial public offerings will increase, and 40% thought the IPO level would remain the same. In addition, only 24% said they believe access to capital will increase, signaling that "funding on the VC [venture capital] level will continue to be challenging," PwC Life Sciences Industry Partner Tracy Lefteroff said during a Feb. 2 conference call on the California Biomedical Industry Report 2010. CHI and PwC surveyed 200 medical device, pharmaceutical and biotech companies about industry challenges, staffing trends and state and federal issues in November 2009

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel